Berenberg analyst Kerry Holford raised the firm’s price target on Novartis (NVS) to CHF 89 from CHF 86 and keeps a Hold rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- FDA announces expanded use of unannounced inspections at foreign facilities
- Trump to sign order streamlining U.S. drug manufacturing regulations, WaPo says
- Trump urges drugmakers to accept lower prices on prescriptions, Bloomberg says
- BioNTech names Ramon Zapata as CFO, succeeding Jens Holstein
- Biotech Alert: Searches spiking for these stocks today